Clinical Technology Organisation (CTO), has announced its preliminary results for the year ended 28 February 2007; revenue grew by 27% and fully diluted adjusted earnings per share grew by 41%
ClinPhone's strong year on year growth is further evidence of the market's continued adoption of technology in clinical trials.
These are ClinPhone's maiden set of full year results since its listing on the London Stock Exchange in June 2006 and are announced after the successful £19.4 million acquisition of DataLabs which completed just five months after the flotation.
This acquisition supports the company's strategy to build and expand upon its very strong position in the clinical trials market.
Other operational highlights for the year include the continued development of new and innovative products, including major functionality enhancements and three new product launches.
In addition, ClinPhone has opened new offices in Australia, San Francisco and Boston as well as relocating its existing Princeton and Chicago offices to larger premises.
Commenting on the results, Steve Kent, CEO of ClinPhone, said: "This has been a highly successful year for ClinPhone with strong year on year growth as the market continues adoption of technology in clinical trials.
"The new products and enhancements we have introduced this year have confirmed our position as market leader.
"The acquisition of DataLabs has further broadened our product offering into the strategically important area of electronic capture of patient data from the patients' physician".
During 2007 ClinPhone will continue to focus its strategy on a number of key areas which will include extending coverage into the market to convert the outstanding 70% of paper-based clinical trials and to continue to bring new and innovative products to its customers.
